Aclaris Therapeutics (ACRS) Research & Development (2014 - 2026)

Aclaris Therapeutics' Research & Development history runs 13 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 35.16% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $56.7 million (up 60.56% YoY), while the FY2025 annual figure was $52.6 million, up 56.75% from the prior year.
• Research & Development for Q1 2026 stood at $15.7 million, down from $16.6 million in the prior quarter.
• The five-year high for Research & Development was $26.6 million in Q4 2023, with the low at $6.0 million in Q3 2024.
• The 5-year median for Research & Development is $15.7 million (2026), against an average of $16.4 million.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 137.8% in 2022, then slumped 75.05% in 2024.
• Aclaris Therapeutics' Research & Development stood at $21.1 million in 2022, then climbed by 26.45% to $26.6 million in 2023, then plunged by 66.13% to $9.0 million in 2024, then surged by 83.74% to $16.6 million in 2025, then retreated by 5.59% to $15.7 million in 2026.
• Business Quant data shows ACRS's Research & Development at $15.7 million in Q1 2026, $16.6 million in Q4 2025, and $13.0 million in Q3 2025.